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The in vitro trypanocidal activities of 4 commercial formulations Ornidyl®, Pentamidine isethionate®, 
Germanin® and Lampit® and their corresponding active principles (Dl-α-difluoromethylornithine, 
pentamidine isethionate, suramine and 5-nitrofuran) were compared against Trypanosoma brucei 
gambiense. Differences of minimum inhibitory concentration (MIC) were observed between Ornidyl® 
and Dl-α-difluoromethylornithine and between Lampit® and 5-nitrofuran. For RO 15 strain and the 
comparison of Ornidyl®/ DFMO, the MIC when using the commercial drug was more than twice the MIC 
value obtained with the active principle. For all 3 trypanosome strains, MICs were identical for Lampit® 
and 5-nitrofuran but the MIC with the commercial formulation was twice the MIC obtained with the 
active principle. The active principles, rather than commercial formulations, should be used for 
standardization of in vitro assay protocols. 
 





Several in vitro methods have been developed for 
studying the drug sensitivity of Trypanosoma brucei 
gambiense, the agent of the chronic form of Human 
African Trypanosomiasis (HAT) or sleeping sickness. The 
chemotherapy of HAT is based on few drugs (W.H.O., 
1998). Cases of treatment failure have been reported in 
Central Africa (Ollivier and Legros, 2001), and drug-
resistant parasites are spreading. For example, in Angola  
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and Sudan, up to 30% of treatment failures has been 
reported by the World Health Organization (W.H.O.) in 
2003. 
Within this context, Drug Resistance Network funded 
by W.H.O. is initiating mapping of drug efficiency against 
HAT in 9 Central African countries; Cameroon, Gabon, 
Central African Republic, Chad, Angola, Uganda, 
Republic of Congo, Democratic Republic of Congo, and 
Equatorial Guinea. Before starting this work, it is 
necessary to standardize the in vitro drug sensitivity 
assay so that results obtained from different laboratories 
can be compared. Unlike in in vitro studies on other 






commercial drugs instead of active principles have been 
mainly used for minimum inhibitory concentration (MIC) 
or IC50 determination for HAT studies (Kaminsky and 
Brun, 1993). The active principle is a pure compound, 
and its use is probably more reliable than commercial 
formulations, especially for long-term or multicentric in 
vitro studies. For drugs obtained from commercial 
sources, storage and interference of excipients could 
influence the in vitro activity.  
In the present study, a comparison of the use of 
commercial drugs versus active principles for in vitro drug 
sensitivity assay on T. b. gambiense is described. In our 
knowledge, this is the first study about such a 
comparison for Human African Trypanosomiasis. We 
tested 3 reference strains (STIB 894, STIB 891, RO15) 
exposed to Ornidyl®, Pentamidine isethionate®, 
Germanin® and Lampit® versus their corresponding 
active principles Dl-α-difluoromethylornithine (DFMO), 
pentamidine isethionate sodium salt, suramine sodium 
salt and 5-nitrofuran, respectively. 
 
 
MATERIALS AND METHODS 
 
Reference strains of T. b. gambiense STIB 894, STIB 891, RO15 
were isolated in Omugo, northwest Uganda and kindly provided by 
the Swiss Tropical Institute in Basel, Switzerland (Matovu et al. 
2001). Parasites were cultured at 37°C in a 5% CO2 incubator. The 
medium used was a 1:1 mixture of RPMI 1640 and MEM, 
supplemented with 15% heat-inactivated human serum and 5% 
heat-inactivated fetal calf serum. Additional supplements were 1% 
2-mercaptoethanol, 1% L-glutamine, and 1% of a mixture 
containing 1 mM sodium pyruvate, 0.5 mM hypoxanthine, 0.05 mM 
bathocuproine sulfonate, 1.5 mM L-cysteine, as previously 
described (Hirumi and Hirumi, 1994). Cultures were monitored daily 
with medium change in order to maintain the trypanosomes in the 
exponential growth phase. 
Ornidyl® and Pentamidine Isethionate BP® were kindly provided 
by Aventis (Antony, France). Germanin®, Lampit®, and 5-nitrofuran 
were provided by Bayer (Wuppertal, Germany). Dl-α- 
difluoromethylornithine (DFMO), pentamidine isethionate sodium 
salt, and suramine sodium salt were purchased from Sigma 
Chemical Co. (St. Louis, MO). Ornidyl® (eflornithine hydrochloride) 
was provided in 200 mg/ml aqueous solution. Stock solutions of 
Lampit® and 5-nitrofuran were prepared in 10 mg/ml DMSO, and 
further dilutions were prepared in sterile water. The final 
concentration of DMSO was < 0.1 %. All other drugs were dissolved 
in sterile water. All drugs and their corresponding active principles 
have the same molecular weight (MW), except for DFMO (MW 219) 
and Ornidyl® (MW 237). 
The long-term viability assay was used to determine the MIC for 
both the active principle and the corresponding commercial 
formulation in the same 24-well plates (Kaminsky and Brun, 1993). 
The trypanosomes (105 parasites/ml) were exposed for 10 days to 
twofold serial drug dilutions ranging from 0.462 to 7.39 µg/ml DFMO 
and 0.5 to 8 µg/ml Ornidyl®, 0.2 to 3.2 µg/ml for both suramine 
sodium salt and Germanin®, 0.0005 to 0.008 µg/ml for both 
Pentamidine isethionate® and pentamidine isethionate sodium salt, 
and 0.625 to 10 µg/ml for both Lampit® and 5-nitrofuran. Cultures 
were monitored and evaluated daily with appropriate medium 
replacement and addition of fresh drug or active principle every 48 
h. The MIC was defined as  the  lowest  concentration  at  which  no  




trypanosomes of normal morphology and motility could be detected 
microscopically. Each test was repeated 6 times for each 
comparison of drug pair.  
 
 
RESULTS AND DISCUSSION 
 
The MIC was identical at each repetition of test (6) for a 
given strain and a given active principle or commercial 
drug. Results are summarized in Table 1. For the 3 
trypanosome strains, MICs of two drug pairs, 
Germanin®/suramine sodium salt and Pentamidine 
isethionate®/pentamidine isethionate sodium salt, were 
similar. Therefore, the purity of the drug powder and 
active principle seemed to be identical. For these two 
drug pairs, the sodium salt forms and commercial 
drug/active principle have identical molecular weights.  
For the comparison of Ornidyl®/DFMO, the MICs 
obtained for both STIB 894 and STIB 891 strains were 4 
and 3.69 µg/ml, respectively. Using Ornidyl®, Matovu et 
al. (2001) found similar results within experimental error. 
For both STIB 894 and STIB 891 strains, the difference of 
molecular weight between DFMO (MW 219) and 
Ornidyl® (MW 237), which is due to the presence of a 
water molecule in the latter, could explain the slight 
difference observed when MIC was expressed in µg/ml 
but the MIC was identical (16.9 µM) when expressed as 
molar concentrations. However, for RO 15 strain, the MIC 
when using the commercial drug (4 µg/ml = 16.9 µM) was 
more than twice the MIC value obtained with the active 
principle (1.85 µg/ml = 8.45 µM). For this strain, Matovu 
et al. (2001) observed a similar MIC using Ornidyl® within 
experimental error. Despite the absence of excipients 
mentioned by the manufacturer and the high solubility of 
both commercial formulation and active principle in water, 
the possible reasons underlying the discordant result 
were not found. Commercial drug is formulated to deliver 
a stable and reliably absorbed compound. This may well 
require additives.  
For all 3 trypanosome strains, MICs were identical for 
Lampit® (2.5 µg/ml) and 5-nitrofuran (1.25 µg/ml). Again, 
the MIC with the commercial formulation was twice the 
MIC obtained with the active principle. The active 
principle 5-nitrofuran was provided as micro-fine 
granules, while Lampit® is tablet. When we dissolved 
them in DMSO, a slight precipitation was observed with 
Lampit® but not with 5-nitrofuran. The solubility of 
Lampit® and 5-nitrofuran seemed to be different. 
Therefore, 5-nitrofuran may have a higher solubility than 
Lampit®, which could explain a higher in vitro 
trypanocidal activity. However, there is need to use 
sensitive and accurate methods (e.g. high pressure liquid 
chromatography) to investigate this problem of solubility.  
Several hypotheses could explain the differences in 
MIC when using active principle and commercial 
formulation,   such   as   solubility   and   interference    of 
 




             Table 1. In vitro activity of trypanocidal drugs. 
 
MIC (µg/ml)* 
Strain Ornidyl® DFMO Germanin® suramine Pentamidine® pentamidine Lampit® 5-nitrofuran
STIB 894 4 3.69 0.8 0.8 0.001 0.001 2.5 1.25 
STIB 891 4 3.69 0.8 0.8 0.002 0.002 2.5 1.25 
R0 15 4 1.85 0.8 0.8 0.001 0.001 2.5 1.25 
                *Minimum inhibitory concentration observed at each of 6 independent experiments. DFMO, Dl-α-difluoromethylornithine. 
 
 
excipients in the commercial formulations with the 
components of culture medium, such as serum. As far as 
we know, there is no previous study on the comparison of 
in vitro trypanocidal activities between different 
pharmaceutical formulations and their corresponding 
active principles. Although MIC determination was 
considered for many years as a reliable technique, these 
results must be confirmed using a more accurate 
technique such as 3H-hypoxanthine incorporation assay 
(Kaminsky and Brun, 1993). These preliminary results 
suggest that standardization of in vitro assay protocols is 
required and should be based on the use of active 
principles to ensure drug quality and purity that permits 
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